ReviewVaccines2025
Viremia Kinetics in Pigs Inoculated with Modified Live African Swine Fever Viruses.
Review in Vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAfrican Swine Fever (ASF) is a viral hemorrhagic disease characterized by diverse clinical and pathological manifestations depending on the virulence of isolates/strains and the immunological status of pigs. The use of modified live viruses (MLVs) is currently the most common approach in developing vaccines against ASF. However, despite the availability of dozens of MLV candidates that meet basic safety and efficacy criteria-such as the absence of severe clinical signs and survival after challenge with a virulent strain-no broadly accepted vaccine has yet been developed. Here, we propose viremia testing as an essential criterion for evaluating candidate ASF vaccines, with levels exceeding 10
methodsWe analyzed ASF MLV vaccines obtained through the deletion of one, two, or more genes, focusing on viremia kinetics after vaccination and challenge with virulent ASFV strains. Post mortem data were used to assess viral persistence in organs.
resultsMost MLV candidates, especially those with single-gene deletions, demonstrated relatively high viremia levels after vaccination and challenge. Viral persistence was frequently detected in organs upon necropsy. MLVs with an additional EP402R gene deletion showed low viremia after vaccination but high levels after challenge. Nevertheless, several candidates with favorable viremia profiles were identified, including those obtained via targeted deletions or serial passaging in cell cultures.
conclusionsIncorporating viremia assessment as a primary screening criterion can significantly narrow down the selection of promising MLV candidates and help accelerate the development of effective emergency vaccines for use in ASF-affected regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.